Video yükleniyor...
Video Yüklenemedi
This just in: exciting news as we continue to #RaiseTheBar for patients facing unmet needs in mental health. The U.S. Food and Drug Administration (U.S. FDA) has granted Breakthrough Therapy designation to DT120 ODT for the treatment of major depressive disorder (MDD), building on our initial designation in generalized... show more
13,726 görüntüleme • 19 gün önce •via X (Twitter)
5 Yorum

The fact that we’re in 2026, we have a catastrophic mental health epidemic and not 1 substancial thing has been done about this crisis is…stunning. Countless therapies held up in clinical trials while people with disabilities continue to get nothing but endlessly watch the dysfunctional, backwards behaviors of people online flourish. We can do better as a country than providing people with absolutely zero.

@FDA @QTRResearch tell me somethin good!

@FDA Mmm FDA Breakthrough Therapy designation ≠ approval. DT120 ODT c interesting MDD signal, but psychedelic trials have a built-in problem: everyone pretends assignment is blinded while the drug is announcing itself in neon. Promising? Yes. Practice-changing? Not yet.

@FDA 👏🏻👏🏻

@FDA Congrats and excellent work.
